Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311)

Eugen Trinka; A Pereira; J Moreira; L Magalhaes; F Ikedo; H Gama

Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311)

Eugen Trinka, A Pereira, J Moreira, L Magalhaes, F Ikedo, H Gama

Department of Neurology

Research output: Contribution to journal › published Abstract (Journal) › peer-review

Original language	English
Journal	NEUROLOGY
Volume	94
Issue number	15
Publication status	Published - 2020
Event	Annual Meeting of the American-Academy-of-Neurology - Toronto, CANADA Duration: 25 Apr 2020 → 1 May 2020

Cite this

Trinka, E., Pereira, A., Moreira, J., Magalhaes, L., Ikedo, F., & Gama, H. (2020). Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311). NEUROLOGY , 94(15).

Trinka, Eugen ; Pereira, A ; Moreira, J et al. / Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311). In: NEUROLOGY 2020 ; Vol. 94, No. 15.

@article{c8cdfc7fd6ae4c38baeddec4b2204b06,

title = "Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311)",

author = "Eugen Trinka and A Pereira and J Moreira and L Magalhaes and F Ikedo and H Gama",

year = "2020",

language = "English",

volume = "94",

journal = "NEUROLOGY ",

issn = "0028-3878",

number = "15",

note = "Annual Meeting of the American-Academy-of-Neurology ; Conference date: 25-04-2020 Through 01-05-2020",

}

Trinka, E, Pereira, A, Moreira, J, Magalhaes, L, Ikedo, F & Gama, H 2020, 'Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311)', NEUROLOGY , vol. 94, no. 15.

Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311). / Trinka, Eugen; Pereira, A; Moreira, J et al.
In: NEUROLOGY , Vol. 94, No. 15, 2020.

Research output: Contribution to journal › published Abstract (Journal) › peer-review

TY - JOUR

T1 - Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311)

AU - Trinka, Eugen

AU - Pereira, A

AU - Moreira, J

AU - Magalhaes, L

AU - Ikedo, F

AU - Gama, H

PY - 2020

Y1 - 2020

M3 - published Abstract (Journal)

SN - 0028-3878

VL - 94

JO - NEUROLOGY

JF - NEUROLOGY

IS - 15

T2 - Annual Meeting of the American-Academy-of-Neurology

Y2 - 25 April 2020 through 1 May 2020

ER -

Trinka E, Pereira A, Moreira J, Magalhaes L, Ikedo F, Gama H. Long-term efficacy and safety of eslicarbazepine acetate (ESL) monotherapy: results from BIA-2093-311/EXT study -the 2-year open-label extension of the ESL study (BIA-2093-311). NEUROLOGY . 2020;94(15).